Defunct Company
Total Trials
5
As Lead Sponsor
3
As Collaborator
2
Total Enrollment
281
NCT01296581
Safety Study of X-82 in Patients With Advanced Solid Tumors
Phase: Phase 1
Role: Lead Sponsor
Start: Feb 28, 2011
Completion: Jan 31, 2017
NCT01674569
Pilot Study of X-82 in Patients With Wet AMD
Phase: Phase 1/2
Start: Oct 31, 2012
Completion: Feb 28, 2015
NCT01784861
VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Everolimus for Treating Patients With Pancreatic Neuroendocrine Tumors
Role: Collaborator
Start: May 3, 2013
Completion: Aug 19, 2020
NCT02146222
VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Docetaxel in Treating Patients With Solid Tumors
Start: Sep 30, 2014
Completion: Dec 31, 2016
NCT02348359
X-82 to Treat Age-related Macular Degeneration
Phase: Phase 2
Start: Mar 16, 2015
Completion: Jan 12, 2018